The Michael J. Fox Foundation for Parkinson's Research

Mission Therapeutics Awarded Follow-On Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation

Retrieved on: 
Tuesday, October 12, 2021

Mission Therapeutics (Mission), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J.

Key Points: 
  • Mission Therapeutics (Mission), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that it has been awarded a Therapeutic Pipeline Program grant of approximately 0.5M USD from The Michael J.
  • Fox Foundation is a great accolade, recognizing the importance of USP30 as a potential therapeutic target for PD, and the quality of Missions chemistry.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.
  • In addition to funding $1 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure.